Patents Assigned to INSTITUTE FOR ADVANCED STUDY
  • Patent number: 11786525
    Abstract: A high-efficiency anti-tumor nano-drug delivery system containing hydralazine (hydralazine-nanoparticles abbreviated as H-NPs) is provided. The drug delivery system takes hydralazine and doxorubicin combined by a ?-? bond as a hydrophobic core and takes dextran as a hydrophilic shell. The high-effective anti-tumor nano-drug delivery system containing hydralazine can increase the vascular permeability and blood perfusion of the tumor site, improve the enrichment and penetration of nanoparticles in the tumor, reduce tumor hypoxia, increase the sensitivity of the tumor to a chemotherapy drug doxorubicin, and significantly improve its anti-tumor effect by expanding the tumor blood vessels and regulating tumor microenvironment (TME).
    Type: Grant
    Filed: March 2, 2023
    Date of Patent: October 17, 2023
    Assignee: SHANGHAI INSTITUTE FOR ADVANCED STUDY ZHE JIANG UNIVERSITY
    Inventors: Ruhong Zhou, Lianxue Zhang
  • Patent number: 10815277
    Abstract: The invention relates to inhibitory nucleotide signal sequences or “INS” sequences in the genomes of lentiviruses. In particular the invention relates to the AGG motif present in all viral genomes. The AGG motif may have an inhibitory effect on a virus, for example by reducing the levels of, or maintaining low steady-state levels of, viral RNAs in host cells, and inducing and/or maintaining in viral latency. In one aspect, the invention provides vaccines that contain, or are produced from, viral nucleic acids in which the AGG sequences have been mutated. In another aspect, the invention provides methods and compositions for affecting the function of the AGG motif, and methods for identifying other INS sequences in viral genomes.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: October 27, 2020
    Assignee: INSTITUTE FOR ADVANCED STUDY
    Inventors: Raul Rabadan, Michael Krasnitz, Harlan Robins, Daniela Witten, Arnold Levine
  • Publication number: 20100203081
    Abstract: The invention relates to inhibitory nucleotide signal sequences or “INS” sequences in the genomes of lentiviruses. In particular the invention relates to the AGG motif present in all viral genomes. The AGG motif may have an inhibitory effect on a virus, for example by reducing the levels of, or maintaining low steady-state levels of, viral RNAs in host cells, and inducing and/or maintaining in viral latency. In one aspect, the invention provides vaccines that contain, or are produced from, viral nucleic acids in which the AGG sequences have been mutated. In another aspect, the invention provides methods and compositions for affecting the function of the AGG motif, and methods for identifying other INS sequences in viral genomes.
    Type: Application
    Filed: July 12, 2007
    Publication date: August 12, 2010
    Applicant: INSTITUTE FOR ADVANCED STUDY
    Inventors: Raul Rabadan, Michael Krasnitz, Harlan Robins, Daniela Witten, Arnold Levine